Login to Your Account

Portola shares slide as top-line betrixaban data just miss mark in phase III VTE trial

By Michael Fitzhugh
Staff Writer

Thursday, March 24, 2016

Shares of Portola Pharmaceuticals Inc. fell by $8.35, or 29.2 percent, on Thursday to close at $20.27 on news that, during a pivotal phase III trial, its once-daily factor Xa inhibitor candidate, betrixaban, fell short of proving statistically better than a standard-of-care anticoagulant for the primary group of patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription